Understanding the Aryl Hydrocarbon Receptor Pathway in Atopic Dermatitis

In this episode of Discourses in Dermatology, Ali Shahbaz, MD, reviews the biology of the aryl hydrocarbon receptor (AhR) pathway and its relevance in atopic dermatitis (AD), using tapinarof as an example of a first-in-class topical therapy that targets this mechanism. Rather than focusing solely on the pharmacology of a single agent, the discussion explores why AhR has emerged as an important therapeutic target and how a growing understanding of skin barrier dysfunction is reshaping the management of inflammatory skin disease.

Atopic dermatitis: More than inflammation alone

Historically, atopic dermatitis has been viewed primarily as an inflammatory disease. While inflammation remains a central feature, advances in our understanding of AD have highlighted a second, equally important component: skin barrier dysfunction.

Dr Shahbaz explains that effective management of AD requires consideration of both of these interconnected processes. Alongside established therapies such as topical corticosteroids and calcineurin inhibitors, newer nonsteroidal agents have expanded treatment options by targeting additional aspects of disease pathophysiology, including restoration of skin barrier function.

The biology of the aryl hydrocarbon receptor

The aryl hydrocarbon receptor is a ligand-activated transcription factor that functions as a molecular sensor within cells. In its inactive state, AhR resides in the cytoplasm. When activated by a ligand, it dissociates from its associated protein complex, translocates into the nucleus, dimerizes with the aryl hydrocarbon receptor nuclear translocator (ARNT), and regulates the transcription of numerous target genes.

One of the distinguishing features of AhR is the remarkable diversity of molecules capable of activating it. These ligands originate from a variety of sources, including environmental pollutants, ultraviolet light photoproducts, microbial metabolites, micropeptides, and tryptophan-derived compounds. Because the skin serves as the body's primary interface with the external environment, AhR is continuously exposed to signals from multiple sources.

Connecting AhR biology to skin barrier function

For dermatologists, one of the most clinically relevant aspects of AhR biology is its role in regulating proteins that maintain skin barrier integrity.

Dr Shahbaz highlights filaggrin as a particularly important example. Filaggrin plays a critical role in maintaining the epidermal barrier, and alterations in its expression contribute to impaired barrier function and increased transepidermal water loss. He also notes that AhR signaling influences additional structural proteins, including loricrin and involucrin, reinforcing the concept that skin barrier integrity depends on multiple coordinated components.

This mechanistic understanding also helps explain observed associations between environmental exposures and AD severity. Rather than viewing AD solely through an immunologic lens, clinicians can also appreciate its structural component, recognizing that barrier dysfunction contributes meaningfully to disease activity.

Restoring barrier function as part of disease management

The skin barrier serves as the body's first line of defense against environmental insults. According to Dr Shahbaz, restoring and maintaining barrier homeostasis represents an important therapeutic objective in inflammatory skin diseases such as AD.

Focusing only on inflammatory pathways may overlook opportunities to improve disease control by addressing the structural abnormalities underlying barrier dysfunction. Supporting barrier restoration therefore complements anti-inflammatory treatment and reflects a more comprehensive approach to disease management.

AhR within the broader inflammatory network

AhR signaling does not function in isolation. Dr Shahbaz discusses its relationship to the broader network of inflammatory pathways involved in AD and psoriasis, including cytokines such as IL-4, IL-13, and IL-31. Appreciating how these pathways intersect provides additional context for understanding the rationale behind emerging targeted therapies.

He notes that tapinarof represents the first topical AhR agonist approved for both atopic dermatitis and plaque psoriasis, introducing a novel therapeutic mechanism into dermatology.

Helping patients understand their disease

Beyond understanding the underlying biology, Dr Shahbaz emphasizes the importance of patient education. Explaining why AD develops and how skin barrier dysfunction contributes to disease can help patients better understand the rationale for treatment selection.

As nonsteroidal topical therapies continue to expand, a clearer understanding of disease mechanisms allows clinicians to connect advances in pathophysiology with practical treatment decisions and more meaningful conversations with patients.